Akari Therapeutics, Plc
AKTX
$0.925
-$0.0249-2.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.92M | 9.71M | 10.71M | 10.24M | 11.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.79M | 15.23M | 17.69M | 18.49M | 19.14M |
| Operating Income | -12.79M | -15.23M | -17.69M | -18.49M | -19.14M |
| Income Before Tax | -12.27M | -17.93M | -19.79M | -20.16M | -20.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.27 | -17.93 | -19.79 | -20.16 | -20.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.27M | -17.93M | -19.79M | -20.16M | -20.13M |
| EBIT | -12.79M | -15.23M | -17.69M | -18.49M | -19.14M |
| EBITDA | -12.78M | -15.22M | -17.68M | -18.47M | -19.13M |
| EPS Basic | -1.26K | -2.74K | -4.12K | -5.62K | -6.28K |
| Normalized Basic EPS | -0.33 | -0.65 | -1.08 | -1.57 | -1.84 |
| EPS Diluted | -1.26K | -2.74K | -4.12K | -5.62K | -6.28K |
| Normalized Diluted EPS | -0.33 | -0.65 | -1.08 | -1.57 | -1.84 |
| Average Basic Shares Outstanding | 90.37M | 68.31M | 47.75M | 32.74M | 25.60M |
| Average Diluted Shares Outstanding | 45.00K | 34.00K | 23.70K | 16.10K | 12.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |